NTLA — Intellia Therapeutics, Inc.

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1652130 ·
Last close
$11.75
Market Cap
$1.65B
52W High
$28.25
52W Low
$7.95
ADV30
3,771,943
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 7,659,000 — -112,760,000 -106,634,000 857,164,000 106,128,000 129,458,000
Mar 2026 15,048,000 — -100,532,000 -96,231,000 758,779,000 134,697,000 137,840,000
Dec 2025 23,017,000 — -98,710,000 -95,786,000 842,127,000 155,464,000 170,733,000
Sep 2025 13,782,000 — -111,477,000 -101,324,000 925,275,000 193,389,000 176,853,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-346,643,000
Investing CF
$-48,469,000
Financing CF
$346,519,000
CapEx
$-2,043,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.36
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,792,959,000
Inventory
—
Receivables
$7,321,000
ST Investments
$331,631,000
EBIT TTM
$-423,479,000
Pretax Income TTM
$-399,975,000
Interest Exp TTM
—
Analysts
17

Yahoo Snapshot (yfinance, live)

Total Revenue
$59,506,000
EBITDA
$-414,400,000
Free Cash Flow
$-249,825,376
Enterprise Value
$1,280,738,432
Total Cash
$437,759,008
Total Debt
$73,410,000
Shares Out
140,126,693
Trailing EPS
$-3.34
Book Value
$5.20
ROE
-55.4%
ROA
-30.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 67,671,000 -440,990,000 -412,694,000 842,127,000 170,733,000 671,394,000 -394,736,000
Dec 2024 57,877,000 -534,263,000 -519,021,000 1,191,015,000 319,059,000 871,956,000 -348,880,000
Dec 2023 36,275,000 -515,291,000 -481,192,000 1,300,977,000 250,808,000 1,050,169,000 -394,086,000
Dec 2022 52,121,000 -458,164,000 -474,186,000 1,520,114,000 284,530,000 1,235,584,000 -333,287,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.60

Max Pain — expiry 2026-10-16

max pain strike: $12.00 · spot: $11.42 · call oi: 10,534 · put oi: 4,762
Expected Move to 2026-10-16: ±$1.60 (14.01%) — implied range $9.82 – $13.02 · ATM straddle on $11.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ABSI Absci Corp $1.67B $9.74 —
CLDX Celldex Therapeutics, Inc. $2.44B $31.10 —
NEOG NEOGEN CORP $3.00B $13.76 —
ACHV ACHIEVE LIFE SCIENCES, INC. $775.88M $7.54 —
QDEL QuidelOrtho Corp $750.22M $10.94 —

News headlines (Yahoo Finance, 1h cache)

Could This Cathie Wood Stock Soar in 2027?
2026-09-27 16:50 · Yahoo
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
2026-09-23 21:49 · Yahoo
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy
2026-09-22 13:20 · Yahoo
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
2026-09-19 04:02 · Yahoo
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?
2026-09-10 18:42 · Yahoo
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform
2026-09-08 14:08 · Yahoo
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z
2026-09-08 12:48 · Yahoo
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
2026-09-08 12:00 · Yahoo
Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In
2026-09-05 16:13 · Yahoo
Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors?
2026-09-05 09:08 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.